Endogenex vs CoverMyMeds
Side-by-side comparison of AI visibility scores, market position, and capabilities
Endogenex develops the ReCET System, a catheter-based endoscopic device that remodels duodenal tissue to treat Type 2 diabetes without surgery; raised $25M Series B in 2024; completed European clinical trials with positive glycemic outcomes;
About
Endogenex is a medical device company headquartered in New Hope, Minnesota, developing endoscopic therapies for metabolic diseases. Its flagship product, the ReCET (Re-Cellularization via Electroporation Therapy) System, uses a catheter-based approach to deliver controlled electrical pulses to the duodenal lining. This non-surgical procedure remodels the duodenal epithelium — the tissue layer believed to play a key role in insulin resistance and glucose regulation — restoring more normal metabolic signaling without removing or bypassing anatomy.
Largest prior authorization network in the US connecting 75K+ pharmacies, 750K+ providers, and all payers. Columbus OH; acquired by McKesson; available free to providers and pharmacies;
About
CoverMyMeds is the largest prior authorization platform in the United States, operating a network that connects more than 750,000 providers, 75,000 pharmacies, and virtually all payers to streamline the authorization process for prescription medications. Founded in 2008 in Columbus, Ohio, and acquired by McKesson Corporation in 2017, CoverMyMeds processes millions of prior authorization requests annually and has become foundational infrastructure for the US pharmacy and specialty medication market. The platform is available at no cost to providers and pharmacies and is funded through health plan and PBM partnerships.\n\nCoverMyMeds' network effect is central to its value: because the platform is used by the vast majority of pharmacies and a very large share of prescribing providers, payers can reach their entire provider and pharmacy network through a single connection. The platform supports real-time benefit checks that show the formulary status and prior authorization requirements for a drug at the point of prescribing, enabling providers to make more informed prescribing decisions before a patient reaches the pharmacy counter. Automated electronic prior authorization (ePA) workflows reduce approval times from days to hours for eligible drug-payer combinations.\n\nAs part of McKesson, CoverMyMeds has expanded its capabilities to include specialty medication access solutions, patient assistance program enrollment, and medication adherence tools. The company's RxCrossroads subsidiary provides hub services for specialty pharmaceutical manufacturers, creating a comprehensive access ecosystem that spans from initial authorization through patient support and adherence management.
Key Details
Capabilities & Ecosystem
Capabilities
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.